Entasis Therapeutics Holdings Inc. (ETTX)
(Delayed Data from NSDQ)
$6.74 USD
-0.14 (-2.02%)
Updated May 3, 2019 04:13 PM ET
After-Market: $6.93 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[ETTX]
Reports for Purchase
Showing records 1 - 20 ( 70 total )
Industry: Medical - Drugs
Acquisition by Innoviva Closes; Terminating Coverage
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
1Q Recap; SUL-DUR''s NDA Filing On Target in Mid-2022; Maintain Neutral, Adjusting PT to $2 Based on Innoviva''s New Offer
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Drugs
ECCMID Presentations Highlight SUL-DUR''s Safety and Efficacy; NDA Filing Expected in Mid-2022; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Drugs
Industry: Medical - Drugs
Q4 Financials; Downgrading to NEUTRAL on Acquisition Proposal
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Industry: Medical - Drugs
4Q Recap: We Expect Innoviva''s Acquisition to Close, As Proposed; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Drugs
3Q21 Recap; U.S. Commercial Preparations Now Underway For SUL-DUR; NDA Filing Expected Mid-2022; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
ATTACK for the Win: Positive Pivotal Results Tees up a mid-2022 NDA Submission
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Drugs
ATTACK Results Support Clear Commercial Opportunity
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Industry: Medical - Drugs
Industry: Medical - Drugs
Nature Publication Highlights ETX0462 and Entasis''Innovative Drug Design Process; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Drugs
KOL Event Highlights Urgent Need For Safe And Effective Treatment Against CRAB
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
2Q21 Recap: SUL-DUR U.S. Launch Preparation Begins As ATTACK Top-line Data on Target for Early 4Q21; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E